Observations supporting this concept include the apparent growth advantage of the BAP1‐inactivated clone over background nevus, the increased risk of cutaneous melanoma in patients with germline BAP1 mutations, and the reported cases of BAP1‐inactivated melanomas.9 This evidence concerns the gene BAP1 and cutaneous melanoma.